Arcellx, Inc.ACLXEarnings & Financial Report
Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.
Revenue
$27.4M
Gross Profit
N/A
Operating Profit
$-35.0M
Net Profit
$-27.2M
Gross Margin
N/A
Operating Margin
-127.8%
Net Margin
-99.3%
YoY Growth
91.5%
EPS
$-0.51
Arcellx, Inc. Q2 FY2024 Financial Summary
Arcellx, Inc. reported revenue of $27.4M (up 91.5% YoY) for Q2 FY2024, with a net profit of $-27.2M (down 14.0% YoY) (-99.3% margin).
Key Financial Metrics
| Total Revenue | $27.4M |
|---|---|
| Net Profit | $-27.2M |
| Gross Margin | N/A |
| Operating Margin | -127.8% |
| Report Period | Q2 FY2024 |
Arcellx, Inc. Annual Revenue by Year
Arcellx, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $107.9M).
| Year | Annual Revenue |
|---|---|
| 2024 | $107.9M |
| 2023 | $110.3M |
Arcellx, Inc. Quarterly Revenue & Net Profit History
Arcellx, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2025 | $8.1M | -79.3% | $-62.3M | -766.0% |
| Q4 FY2024 | $15.3M | -75.8% | $-47.1M | -308.4% |
| Q3 FY2024 | $26.0M | +74.0% | $-25.9M | -99.4% |
| Q2 FY2024 | $27.4M | +91.5% | $-27.2M | -99.3% |
| Q1 FY2024 | $39.3M | +119.2% | $-7.2M | -18.3% |
| Q4 FY2023 | $63.1M | — | $19.8M | 31.4% |
| Q3 FY2023 | $15.0M | — | $-39.3M | -263.0% |
| Q2 FY2023 | $14.3M | — | $-23.9M | -166.8% |
Income Statement
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.3M | $15.0M | $63.1M | $39.3M | $27.4M | $26.0M | $15.3M | $8.1M |
| YoY Growth | N/A | N/A | N/A | 119.2% | 91.5% | 74.0% | -75.8% | -79.3% |
Balance Sheet
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $623.5M | $614.2M | $825.1M | $779.7M | $734.3M | $764.9M | $711.3M | $648.1M |
| Liabilities | $329.9M | $348.1M | $339.8M | $283.1M | $247.1M | $281.9M | $256.5M | $231.2M |
| Equity | $293.7M | $266.1M | $485.4M | $496.6M | $487.2M | $483.0M | $454.8M | $416.9M |
Cash Flow
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-22.6M | $-10.1M | $58.2M | $-31.9M | $-36.2M | $30.7M | $-46.0M | $-63.1M |